CAR-T cell therapy has transformed the treatment landscape for blood cancers, offering new hope to patients with relapsed or refractory conditions. In China, significant progress is being made in both clinical application and research for hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. This category highlights the latest trends, approvals, clinical trials, and innovations in CAR-T therapy for blood cancers in China—covering both international products and locally developed treatments. Explore how China is leading advancements in personalized, cell-based immunotherapy.
CAR-T therapy is no longer being explored only for relapsed or refractory multiple myeloma. New research is investigating its use in newly diagnosed and high-risk patients, with the potential to achieve deeper and more durable remissions.
The National Comprehensive Cancer Network (NCCN) has released Acute Lymphoblastic Leukemia, Version 2.2026, providing an updated framework for the management of acute lymphoblastic leukemia (ALL). One of the most notable
Five-year follow-up data from Yescarta (axi-cel) continues to demonstrate durable survival and long-term remission in patients with relapsed or refractory large B-cell lymphoma, supporting its role as a potential curative treatment and establishing a new standard of care in China.
OL-101, a novel BCMA/GPRC5D dual-target CAR-T cell therapy, achieved 100% ORR and deep responses in a Phase I study of heavily pretreated R/R multiple myeloma patients, including those with prior CAR-T exposure and extramedullary disease, presented at EHA 2026.
CAR-T cell therapy, antibody-drug conjugates (ADCs), and bispecific antibodies are transforming the treatment landscape for multiple myeloma. Discover how these innovative immunotherapies work and the benefits they offer patients with relapsed or refractory disease.
A new real-world multicenter study in patients with relapsed or refractory large B-cell lymphoma shows that second-line CAR-T cell therapy is associated with a lower hematologic toxicity burden, improved safety profile, and favorable survival outcomes compared with later-line treatment settings.
A new modeling study reveals that lowering tumor burden before CAR-T infusion could significantly improve outcomes in lymphoma, offering a new strategy to enhance long-term remission.
A multicenter study published in Cytotherapy shows CD19 CAR-T therapy delivers high remission rates and promising long-term survival for B-ALL patients who relapse after allogeneic stem cell transplantation.
New Phase II data from China demonstrate that relma-cel CAR-T therapy delivers high response rates and durable survival in heavily pretreated relapsed/refractory mantle cell lymphoma patients.
As CAR-T therapy reshapes treatment for multiple myeloma worldwide, China is emerging as a key alternative with strong research, lower costs, and faster access.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.